Craig Gracey
Known title: Chief Accounting OfficerCIK: 0002021724
Associated companies
Transaction History
| OMDA | ▼ Sell | Open Market | 644 | $14K | 9/9/2026 | View on chart |
| OMDA | ▼ Sell | Tax Withholding | 385 | $9K | 9/1/2026 | View on chart |
| OMDA | ▲ Buy | Option Exercise | 1,042 | $7K | 8/10/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 1,042 | $26K | 8/10/2026 | View on chart |
| OMDA | ▲ Buy | Option Exercise | 1,041 | $7K | 7/13/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 1,041 | $25K | 7/13/2026 | View on chart |
| OMDA | ▲ Buy | Option Exercise | 637 | $4K | 7/1/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 637 | $15K | 7/1/2026 | View on chart |
| OMDA | ▲ Buy | Option Exercise | 405 | $3K | 6/30/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 405 | $9K | 6/30/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 2,083 | $44K | 6/29/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 2,084 | $42K | 6/26/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 2,083 | $40K | 6/24/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 2,083 | $37K | 6/22/2026 | View on chart |
| OMDA | ▼ Sell | Open Market | 6,894 | $120K | 6/12/2026 | View on chart |
| OMDA | ▼ Sell | Tax Withholding | 385 | $7K | 6/1/2026 | View on chart |
| OMDA | ▲ Buy | Grant | 16,470 | $0 | 3/5/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation
Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.
Omada Health Sets Q3 2026 Earnings Call, Investors Question Valuation. Omada Health will report its third quarter 2026 results on November 5 and host a conference call. Recent commentary highlights the company’s growth but raises concerns about its competitive moat and long‑term price targets. Analysts note a high trailing P/E of 260.2 and a wide target range of $22.00 to $35.00. The upcoming call may clarify how the firm plans to address these valuation questions.